Comparison Study of Efficacyinvolving Intravitreal Ranibizumab Versus Standard Laser Mono Therapy in Patients with Visual Impairment Due To Diabetic Macula Edema

Purpose:. To compare efficacy of intravitreal Ranibizumab (ivR) and standard laser in patients with visual impairment due to diabetic macular edema (DME) in terms of best corrected visual acuity(BCVA) and central macular thickness(CMT) Design:Single blind hospital based comparative type of randomized follow-up study.: Methods: A total of 80 eyes of 80 patients with centre-involving CSME (both diffuse and focal) were included.Subjects were subjected to treatment with either ivR(3 consecutive monthsand PRN dosing thereafter or modified macular laser therapy (MLT).Treatment outcomes in terms of BCVA and reduction in CMT were measured. Results: There was a statistically significant change in the BCVA compared to baseline in both the groups.The average gain in visual acuity was higher in the ivRgroup.(8.825 ETDRS letters compared with 3.09ETDRS letters in the laser only group at 12 months of follow up.The decrease from the average baseline CMT was higher in the intravitreal antiVEGF group (74.22microns compared with 28.54 microns in the laser only group at Conclusion: Both treatment modalities are effective in treatment of DME. Intravitreal Ranibizumab showed greater efficacy both in terms of final BCVA and reduction in CMT. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any products discussed in this article.